CN112930179A - 治疗睡眠呼吸暂停的方法和组合物 - Google Patents

治疗睡眠呼吸暂停的方法和组合物 Download PDF

Info

Publication number
CN112930179A
CN112930179A CN201980071524.0A CN201980071524A CN112930179A CN 112930179 A CN112930179 A CN 112930179A CN 201980071524 A CN201980071524 A CN 201980071524A CN 112930179 A CN112930179 A CN 112930179A
Authority
CN
China
Prior art keywords
oxybutynin
composition
atomoxetine
muscarinic receptor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980071524.0A
Other languages
English (en)
Chinese (zh)
Inventor
L·G·米勒
R·法卡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epuning Delaware
Original Assignee
Epuning Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epuning Delaware filed Critical Epuning Delaware
Publication of CN112930179A publication Critical patent/CN112930179A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980071524.0A 2018-10-31 2019-07-23 治疗睡眠呼吸暂停的方法和组合物 Pending CN112930179A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753420P 2018-10-31 2018-10-31
US62/753,420 2018-10-31
PCT/US2019/043065 WO2020091862A1 (en) 2018-10-31 2019-07-23 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
CN112930179A true CN112930179A (zh) 2021-06-08

Family

ID=67539629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980071524.0A Pending CN112930179A (zh) 2018-10-31 2019-07-23 治疗睡眠呼吸暂停的方法和组合物

Country Status (9)

Country Link
US (3) US20210401790A1 (https=)
EP (1) EP3873454A1 (https=)
JP (2) JP2022506113A (https=)
KR (1) KR20210084481A (https=)
CN (1) CN112930179A (https=)
AU (1) AU2019370091A1 (https=)
CA (1) CA3117766A1 (https=)
MX (2) MX2021004883A (https=)
WO (1) WO2020091862A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021920A (ko) * 2021-06-17 2024-02-19 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 노르에피네프린 재흡수 억제제
MX2024007764A (es) * 2021-12-22 2024-07-04 Bayer Ag Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
US20250049779A1 (en) * 2021-12-22 2025-02-13 Bayer Aktiengesellschaft Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
CN119789855A (zh) * 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CN1708302A (zh) * 2002-10-31 2005-12-14 伊利诺伊大学评议会 睡眠呼吸暂停的药理学疗法
CN106714790A (zh) * 2014-07-22 2017-05-24 托马斯·P·杜利 使用β肾上腺素能受体拮抗剂和毒蕈碱受体拮抗剂组合的治疗惊恐和焦虑症状的药物组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CH695982A5 (de) * 2001-03-06 2006-11-15 Lilly Co Eli Inhibitor der Monaminaufnahme.
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
JP2012176958A (ja) * 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
AU2018260666B2 (en) * 2017-04-28 2022-07-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
CN1660435A (zh) * 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
CN1708302A (zh) * 2002-10-31 2005-12-14 伊利诺伊大学评议会 睡眠呼吸暂停的药理学疗法
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CN106714790A (zh) * 2014-07-22 2017-05-24 托马斯·P·杜利 使用β肾上腺素能受体拮抗剂和毒蕈碱受体拮抗剂组合的治疗惊恐和焦虑症状的药物组合物和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
-: "Atomoxetine and Oxybutynin in Obstructive Sleep Apnea (ATOSA)", pages 3, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/show/NCT02908529> *
DONNA J. BELLE;等: "Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 42, 31 December 2002 (2002-12-31), pages 1219 - 1227 *
李彬;等: "帕金森病非运动症状的药物治疗", 安徽医学, vol. 29, no. 03, 15 May 2008 (2008-05-15), pages 333 - 335 *

Also Published As

Publication number Publication date
MX2024013184A (es) 2024-12-06
JP2022506113A (ja) 2022-01-17
CA3117766A1 (en) 2020-05-07
EP3873454A1 (en) 2021-09-08
US20210401790A1 (en) 2021-12-30
WO2020091862A1 (en) 2020-05-07
MX2021004883A (es) 2021-08-05
JP2024088740A (ja) 2024-07-02
US20250325510A1 (en) 2025-10-23
KR20210084481A (ko) 2021-07-07
US20250114321A1 (en) 2025-04-10
AU2019370091A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
US20250186371A1 (en) Methods and compositions for treating sleep apnea
US20260007618A1 (en) Methods and compositions for treating sleep apnea
US20250114321A1 (en) Methods and compositions for treating sleep apnea
HK40117857A (en) Methods and compositions for treating sleep apnea
HK40031779B (en) Methods and compositions for treating sleep apnea or simple snoring
HK40031779A (en) Methods and compositions for treating sleep apnea or simple snoring
EA047115B1 (ru) Способы и композиции для лечения апноэ сна

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210608